Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 92.65B 503B 82.98B 76.33B 69.16B 129B 8,798B 132B 910B 365B 4,628B 348B 340B 14,594B P/E 2026 *
19.2x
P/E 2027 * 17.8x
Enterprise Value 85.05B 462B 76.17B 70.07B 63.49B 119B 8,076B 121B 836B 335B 4,248B 319B 312B 13,397B EV / Sales 2026 *
4.83x
EV / Sales 2027 * 4.39x
Free-Float
71.06%
Yield 2026 *
0.43%
Yield 2027 * 0.46%
1 day+15.11%
1 week+25.10%
Current month+27.91%
1 month+27.91%
3 months+37.49%
6 months+43.73%
Current year+18.07%
1 week 71.76
Extreme 71.76
84.06
1 month 60.22
Extreme 60.22
84.06
Current year 50
Extreme 50
84.06
1 year 50
Extreme 50
84.06
3 years 44.82
Extreme 44.82
111.72
5 years 44.82
Extreme 44.82
111.72
10 years 18.16
Extreme 18.160832
111.72
Manager TitleAgeSince
President 66 2000-12-31
Chief Executive Officer 73 1988-01-07
Director of Finance/CFO 55 2024-02-04
Director TitleAgeSince
Chairman 73 2023-06-08
Director/Board Member 85 1991-05-31
Director/Board Member 76 1988-01-07
Change 5-day change 1-year change 3-year change Capi.($)
+15.11%+25.10% - - 92.65B
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average +3.07%+5.90%+46.59%+83.14% 473.55B
Weighted average by Cap. +1.49%+6.60%+50.88%+98.31%

Financials

2026 *2027 *
Net sales 17.6B 95.59B 15.77B 14.5B 13.14B 24.56B 1,672B 25.02B 173B 69.43B 879B 66.07B 64.66B 2,773B 18.59B 101B 16.65B 15.31B 13.87B 25.93B 1,765B 26.42B 183B 73.3B 928B 69.75B 68.27B 2,928B
Net income 5.41B 29.4B 4.85B 4.46B 4.04B 7.56B 514B 7.7B 53.2B 21.35B 270B 20.32B 19.89B 853B 5.68B 30.82B 5.08B 4.68B 4.24B 7.92B 539B 8.07B 55.76B 22.38B 283B 21.3B 20.85B 894B
Net Debt -7.6B -41.29B -6.81B -6.26B -5.68B -10.61B -722B -10.81B -74.69B -29.98B -380B -28.53B -27.93B -1,198B -10.97B -59.56B -9.82B -9.04B -8.19B -15.3B -1,041B -15.59B -108B -43.25B -548B -41.16B -40.29B -1,728B
Projected Income Statement - Annual - Regeneron Pharmaceuticals, Inc.
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Date Price Change Volume
26-10-30 R$83.72 +15.11% 856
26-10-28 R$72.73 +0.68% 215
26-10-27 R$72.24 -0.48% 734
26-10-26 R$72.59 +8.47% 3,596
26-10-23 R$66.92 -3.24% 8,845
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Regeneron Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
927.89USD
Average target price
869.07USD
Spread / Average Target
-6.34%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Regeneron Pharmaceuticals, Inc.